Member Info for Inthetin

What a despicable, mean old effer.

Hi tonyj

IMO, the market does not believe that Cyan has an ongoing commercial relationship with Genus.

If JC, HP & DJP plus a few more of the recent placing investors know differently, JC should notify the market that the working relationship is sound. He doesn't need to talk numbers, just a little reassurance would suffice.

This endless silence on the Genus front is costing shareholders a lot of money and might have created an extremely nice opportunity for others too.

Attempting to distract by talking about everywhere other than India simply isn't washing.

If trust could go any lower it would.

An effing hopeless way to run a company. Little wonder it is pushed from pillar to post - Cyan is probably a laughing stock in India.

Have a fun weekend.

ITT

Just as importantly, over the last 6 months, Genus have made their shareholders 220% more than Cyan have made theirs.

What a ****show.

I can see now (in the Annual Report) that the share options have a life of 10 years.

If we stick with the 10/11/2021 grant date, I think that the 14.5p options expired over a week ago.

Could even be 2 years, not 3.

yesterday's rns says:-

in addition to the above share options john cronin and heather pea**** currently hold the following shares in the company's jsop blah blah blah:

john cronin & heather pea**** grant date - 10/11/21 / expiry date 10/11/26 @ 0.145p

however, the 05/07/21 rns (restructuring of share incentive arrangements) says:

these awards are expected to be made as soon as practicable and shall vest as follows:-

33% of the new 14.5p options shall vest immediately, 33% vesting after 12 months and the remaining 33% vesting after 24 months.

that's 3 years, not 5. shouldn't they be expiring in november 2024 at the latest, not november 2026.

have shareholders been notified of any 2-year extension?

Hi CB

It's not our job to spot the errors in these RNSs. They need to take their work a bit more seriously. If they did, these errors wouldn't continually happen but I get the impression that they just don't care.

I am seriously considering selling my Cyan holding and investing some of it in MINI instead. I have been investing modest amounts with Mr Williams for a few months. Eventually, the fund could be holding 14% of Cyan's shares. Somehow or other, GW seems to have outmanoeuvred the BoD.

GL

ITT

Two years ago, Hardman were saying:-

"The analysis produces an implied fair enterprise value of £87.9m and an implied fair equity value of £89.6m (equating to £0.41 per share). These valuation outcomes are materially higher than the current enterprise value of £24.5m and market capitalisation of £26.2m."

After the BoD have 'given' a huge chunk of the company away, this now translates to a fair equity (pie in the sky) value of 27p per share instead of 41p (a 34% decrease).

Great work.

That's my guess BTW. Don't go looking for the RNS.

Oh dear, it goes from bad to worse.

*Revenue in line with market expectations.

*Losses much higher than market expectations.

Unfortunately, Cyan isn't a business that's attempting to make a profit - it's an ego trip for one guy, which is why the UK taxpayer shouldn't be propping it up with R&D tax credits & EIS relief for wealthy individuals who, by the way, shouldn't be receiving State Benefits. Talk about undeserving scroungers.

Apart from tenbagging, I wish that I'd never stumbled across this crock of proverbial.

Good luck with getting your monthly reports.

"If you ain't first, you're last."

Hi jakeandelwood

My advice (for what it's worth) to JC & Co is to button it for a while. There's nothing that they can say that will impact positively on the SP - until they release a substantial Genus order (joke).

Cheers

ITT

Am I correct in saying that one third of the 17p options will lapse on 31/01/2024?

Hi jakeandelwood

Remember, Creo came first.

I haven't checked the figures for the outfit that came 12th.

Enough about this prestigious award, let's have the RNS replacing Friday's.

Don't they do embarrassment?

here we go. are you ready?

"congratulations to creo medical for achieving a record growth rate of 9,260% between 2019 and 2021."

dig a tiny bit deeper and you find that their revenue grew from £13k in 2019 to £227k in 2021.

this is all part of the box ticking required to ensure that they don't **** up cyan's eis qualification, being probably the oldest 'start-up' to ever receive eis support.

Hi jakeandelwood

I'll have you know that the 50 fastest-growing businesses in each region have been identified through robust research conducted by the Ideas Forums team, led by Professor Dylan Jones-Evans, the creator of the Wales Fast Growth 50 and a leading entrepreneurship academic, who loves a good knees up.

Apparently, it's an initiative that has been running in Wales for 25 years.

www.fastgrowth50.com/midseast2023/

I'm going to have a look for last year's Welsh winner - results later.

Effing hopeless.

ITT

Even if the BoD are not directly responsible for the dramatic decline in the SP, they haven't been shy in coming forward and taking full advantage of its weakness, after doing nothing whatsoever in their power to support it.

I wonder at what price the next coordinated selling by our major shareholders has been agreed at? It will become apparent in due course.

They were in such a rush to get the share options RNS out on Friday, I'm sure that there's yet another typo.

Heather's don't total 682,642, they total the same as JC's (i.e. 1,548,949).

Let's have another RNS on Monday to tidy this up, please.